Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

BACKGROUND: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRP...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Rathkopf, D. E., Smith, M. R., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Higano, C. S., Alumkal, J. J., Hauke, R., Tutrone, R. F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D. S., Yu, M. K., de Boer, C. J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H. I., Antonarakis, E. S.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834046/
https://ncbi.nlm.nih.gov/pubmed/28633425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx283
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items